Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study-Reference-Cited by-同舟云学术

Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Liu Fangchao¹²,Gao Jingtao¹,Gao Mengqiu³,Liu Yuhong¹,Shu Wei¹,Xie Li³,Sun Yuxian¹,Zhang Lijie¹,Li Liang¹,Pang Yu⁴^ORCID

Affiliation:

1. Clinical Center on TB, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, People’s Republic of China

2. Department of Science and Technology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, People’s Republic of China

3. Department of Tuberculosis, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, People’s Republic of China

4. Department of Bacteriology and Immunology, Beijing Chest Hospital, Capital Medical University/Beijing Tuberculosis & Thoracic Tumor Research Institute, Beijing, People’s Republic of China

Abstract

Corrected QT duration (QTc) interval prolongation is the most frequent adverse event associated with bedaquiline (BDQ) use. It may affect the safety of antituberculosis therapy, which leads to the consequent demands of needing to monitor during therapy.

Funder

MOST | National Major Science and Technology Projects of China

Beijing Hospital Authority Ascent Plan

Beijing Hospital Authority Clinical Medicine Development of Special Funding

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02033-21

Reference36 articles.

1. Management of drug-resistant tuberculosis

2. World Health Organization. 2020. Global tuberculosis report. World Health Organization, Geneva, Switzerland.

3. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

4. Bedaquiline: First FDA-approved tuberculosis drug in 40 years

5. Bactericidal mode of action of bedaquiline

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updates in pulmonary drug‐resistant tuberculosis pharmacotherapy: A focus on BPaL and BPaLM;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-01-25